This week, Abbott Laboratories resolved its appeal of a $495 million verdict, and a document that most people will never see was filed in a Missouri appeals court. No big announcement. No press conference. At least for one family, it was just a document and the official conclusion of a case that had been dragging through the courts for two years.
St. Louis rendered the initial decision in 2024. A jury determined that an Illinois girl developed necrotizing enterocolitis, a dangerous and frequently fatal bowel disease that mainly affects premature newborns, as a result of using Abbott’s specialized preterm infant formula. $495 million felt like a huge sum to the jury. Abbott filed an appeal. In May 2026, the Missouri Court of Appeals upheld the ruling. Then Abbott pushed for the state Supreme Court, taking it a step further. Silently, it settled after that.
The conditions were not made public. This is typical in situations like this, but it does leave some room for ambiguity. The Gill v. Abbott case is known to be closed as a result of the settlement. Everything else is still up for debate.
The manufacturer of Enfamil formula, Abbott and Reckitt’s Mead Johnson division, is currently facing about 1,000 similar lawsuits. A consolidated federal proceeding in Illinois is home to more than 800 of those cases. Others are proceeding independently through state courts in Illinois, Pennsylvania, and Missouri. Currently taking place in Chicago is a federal bellwether trial, which is intended to provide both sides with an indication of how juries react to the main points of contention. It’s still unclear if the outcome of that trial will result in a decision that changes the course of events.
The unique nature of the product is what sets this lawsuit apart. These are not the cans of Enfamil or Similac that are found on store shelves. Cow’s milk-based formulas and human milk fortifiers designed especially for premature infants in hospital NICUs—places where parents frequently have little control over what their babies receive and where medical decisions are made quickly—are the products at the center of these cases. Legally and emotionally, that distinction is important. In some of the most stressful situations parents may encounter, these patients are among the most vulnerable that can be imagined.
Reckitt and Abbott have consistently insisted that NEC is not caused by their products. According to their position, which is supported by a 2024 report from U.S. regulatory agencies and a working group convened by the NIH, the increased risk of NEC in premature infants is associated with the lack of breast milk rather than the presence of formula. It’s a significant distinction with weight in science. However, it hasn’t always been convincing to juries in state courts. Some have taken the companies’ side. Some haven’t. That conflicting record illustrates how difficult this science is in reality and how it can be interpreted differently depending on how it is presented.
Back in 2024, Abbott CEO Robert Ford hinted that the lawsuit might eventually force the company to completely remove preterm formula products from the market. That sent shivers down neonatology’s spine, whether it was a real warning or a pressure ploy. These products cover a specific need, especially in situations where there is insufficient or no donor breast milk. It wouldn’t be easy to lose them.
As this case develops, it seems that nothing significant is resolved by the Missouri settlement. It matters that the ordeal of one family has come to some sort of conclusion. However, there are still a thousand pending cases. There will eventually be an outcome from the federal bellwether. There will be more state trials. The families pursuing these claims are not going away, and Abbott and Reckitt are still very much involved in this battle.
The Gill settlement confirms what litigation observers likely already suspected: Abbott determined it wasn’t worthwhile to pursue an appeal of this specific verdict. It’s unclear if that indicates weariness or confidence.
